financetom
Business
financetom
/
Business
/
Stantec's Q2 adjusted EPS meets estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stantec's Q2 adjusted EPS meets estimates
Aug 13, 2025 2:38 PM

Overview

* Stantec ( STN ) Q2 net revenue rises 6.9% to C$1.6 bln, missing expectations

* Adjusted EPS meets expectations at C$1.36, adjusted EBITDA beats estimates

Outlook

* Stantec ( STN ) raises 2025 net revenue growth guidance to 10%-12%

* Company expects adjusted EPS growth of 18.5%-21.5% in 2025

* Stantec ( STN ) increases adjusted EBITDA margin guidance to 17%-17.4%

* Company sees adjusted ROIC above 12.5% for 2025

Result Drivers

* ORGANIC GROWTH - Stantec ( STN ) achieved 4.8% organic growth, with significant contributions from Water and Energy & Resources sectors

* ACQUISITIONS - Recent acquisitions, including Page, bolstered the company's Buildings business and contributed to revenue growth

* EXPENSE MANAGEMENT - Lower administrative and marketing expenses improved adjusted EBITDA margin by 120 basis points

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss C$1.60 C$1.64

Revenue bln bln (10

Analysts

)

Q2 Meet C$1.36 C$1.36

Adjusted (10

EPS Analysts

)

Q2 EPS C$1.19

Q2 Beat C$284.40 C$283.50

Adjusted mln mln (11

EBITDA Analysts

)

Q2 Order C$7.90

Backlog bln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the construction & engineering peer group is "buy"

* Wall Street's median 12-month price target for Stantec Inc ( STN ) is C$155.00, about 3% above its August 12 closing price of C$150.32

* The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Truckload carrier Werner posts Q3 loss per share, misses estimates on challenging freight environment
Truckload carrier Werner posts Q3 loss per share, misses estimates on challenging freight environment
Oct 30, 2025
Overview * Werner Enterprises ( WERN ) Q3 revenue rises 3% to $771.5 mln, beating analyst expectations * Adjusted loss per share for Q3 misses EPS analyst expectations, reflecting challenging freight environment * Company recorded $18 mln settlement for a class action lawsuit, impacting Q3 results Outlook * Company expects TTS truck count to decrease by 2% to remain flat...
United Therapeutics Insider Sold Shares Worth $4,953,760, According to a Recent SEC Filing
United Therapeutics Insider Sold Shares Worth $4,953,760, According to a Recent SEC Filing
Oct 30, 2025
04:43 PM EDT, 10/30/2025 (MT Newswires) -- Paul A Mahon, Executive Vice President & General Counsel, on October 30, 2025, sold 11,000 shares in United Therapeutics ( UTHR ) for $4,953,760. Following the Form 4 filing with the SEC, Mahon has control over a total of 36,781 common shares of the company, with 36,781 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1082554/000123158925000009/xslF345X05/primarydocument.xml...
MDA Issuing Statement In Response To Share Price Fluctuations; Shares Fell Near 16% Today
MDA Issuing Statement In Response To Share Price Fluctuations; Shares Fell Near 16% Today
Oct 30, 2025
04:44 PM EDT, 10/30/2025 (MT Newswires) -- MDA Space ( MDALF ) , a mission partner to the rapidly expanding global space industry, after trade Thursday issued a statement in response to share price fluctuations, after its stock dropped near 16% today. MDA Space ( MDALF ) is monitoring fluctuations in our share price that appear to be the result...
Medical devices maker Stryker's Q3 sales beat estimates on orthopaedics strength
Medical devices maker Stryker's Q3 sales beat estimates on orthopaedics strength
Oct 30, 2025
Overview * Stryker Q3 net sales rise 10.3% to $6.1 bln, beating analyst expectations * Adjusted EPS for Q3 increases 11.1% to $3.19, exceeding analyst estimates * Company raises full-year guidance, citing strong sales momentum and margin expansion Outlook * Stryker raises 2025 organic net sales growth guidance to 9.8%-10.2% * Company expects 2025 adjusted EPS between $13.50 and $13.60...
Copyright 2023-2026 - www.financetom.com All Rights Reserved